SCHEMBL276532

SCHEMBL276532

Oc1cnnc2ccccc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR3 P46089 2/20 0.50
IDO1 P14902 1/20 0.40
TGFBR1 P36897 1/20 0.40
ERN1 O75460 1/20 0.40
MYC P01106 1/20 0.38
MAX P61244 1/20 0.38
LMNA P02545 2/20 0.36
HTT P42858 1/20 0.36
CYP1A2 P05177 4/20 0.36
LCK P06239 1/20 0.36
MAP2K3 P46734 1/20 0.36
MAP2K6 P52564 1/20 0.36
BTK Q06187 1/20 0.36
MAP3K19 Q56UN5 1/20 0.36
NEK10 Q6ZWH5 1/20 0.36
KDM4E B2RXH2 2/20 0.35
CYP2C19 P33261 1/20 0.35
ALDH1A1 P00352 2/20 0.34
RAB9A P51151 2/20 0.34
KMT2A Q03164 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4864194 0.98 GPR3 (0.48) GPR3IDO1TGFBR1ERN1MYC
SCHEMBL8412384 0.87 KMT2A (0.42) GPR3TGFBR1ERN1LMNAHTT
SCHEMBL27665980 0.78 TGFBR1 (0.49) GPR3IDO1TGFBR1KDM4EALDH1A1
SCHEMBL637764 0.76 GPR3 (0.48) GPR3TGFBR1LMNAHTTCYP1A2
SCHEMBL12861090 0.74 SRC (0.32)
SCHEMBL3883304 0.73 GPR3 (0.50) GPR3TGFBR1LMNAHTTCYP1A2
SCHEMBL276531 0.73 GPR3 (0.50) GPR3TGFBR1LMNAHTTCYP1A2
SCHEMBL21532813 0.73 GPR3 (0.50) GPR3TGFBR1LMNAHTTCYP1A2
SCHEMBL1960424 0.73 GPR3 (0.50) GPR3TGFBR1LMNAHTTCYP1A2
SCHEMBL436407 0.73 GPR3 (0.50) GPR3TGFBR1CYP1A2KDM4ECYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 342 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4727939-A1 5-(CINNOLIN-6-YL)THIAZOLE COMPOUNDS FOR TREATING NEUROLOGICAL DISORDERS Prothena Biosciences Limited (IE) 2026-04-22 EP claimed
WO-2024259116-A1 5-(CINNOLIN-6-YL)THIAZOLE COMPOUNDS FOR TREATING NEUROLOGICAL DISORDERS PROTHENA BIOSCIENCES LIMITED (IE) 2024-12-19 WO claimed
US-4620000-A Method for preparing 4-hydroxycinnolines in a pH controlled system SHELL OIL COMPANY (US) 1986-10-28 US claimed
EP-4727939-A1 5-(CINNOLIN-6-YL)THIAZOLE COMPOUNDS FOR TREATING NEUROLOGICAL DISORDERS Prothena Biosciences Limited (IE) 2026-04-22 EP disclosed
US-20260008767-A1 SOMATOSTATIN MODULATORS AND USES THEREOF CRINETICS PHARMACEUTICALS INC (US) 2026-01-08 US disclosed
WO-2024259116-A1 5-(CINNOLIN-6-YL)THIAZOLE COMPOUNDS FOR TREATING NEUROLOGICAL DISORDERS PROTHENA BIOSCIENCES LIMITED (IE) 2024-12-19 WO disclosed
US-20240207263-A1 SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE AND USES THEREOF SUZHOU ZANRONG PHARMA LIMITED (CN) 2024-06-27 US disclosed
CN-117659025-A TOLL-like receptor 8 (TLR 8) specific antagonists, methods of making and uses thereof 科罗拉多州立大学董事会法人团体 2024-03-08 CN disclosed
CN-117586191-A TOLL-like receptor 8 (TLR 8) specific antagonists, methods of making and uses thereof 科罗拉多州立大学董事会法人团体 2024-02-23 CN disclosed
CN-117586108-A TOLL-like receptor 8 (TLR 8) specific antagonists, methods of making and uses thereof 科罗拉多州立大学董事会法人团体 2024-02-23 CN disclosed
EP-4308569-A1 SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE AND USES THEREOF Suzhou Zanrong Pharma Limited (CN) 2024-01-24 EP disclosed
EP-0277791-A2 Cinnoline-carboxamides and process for their preparation FARMITALIA CARLO ERBA S.r.l. (IT) 1988-08-10 EP disclosed
US-4758639-A Process for production of vinyl polymer SHIN-ETSU CHEMICAL CO., LTD. (JP) 1988-07-19 US disclosed
US-4757124-A Suspension or emulsion polymerizing vinyl chloride monomer or mixture of vinyl chloride with vinyl monomer copolymerizable therewith in reactor with walls coated with antiscaling compound containing dye or pigments SHIN-ETSU CHEMICAL CO., LTD. (JP) 1988-07-12 US disclosed
US-4666499-A Herbicidal 2 methyl-4-phosphinylcinnolinium hydroxide inner salts E. I. DU PONT DE NEMOURS AND COMPANY (US) 1987-05-19 US disclosed
US-4620000-A Method for preparing 4-hydroxycinnolines in a pH controlled system SHELL OIL COMPANY (US) 1986-10-28 US disclosed
US-4620000-A Method for preparing 4-hydroxycinnolines in a pH controlled system SHELL OIL COMPANY (US) 1986-10-28 US disclosed
US-4620000-A Method for preparing 4-hydroxycinnolines in a pH controlled system SHELL OIL COMPANY (US) 1986-10-28 US disclosed
EP-0172427-A2 Process for production of vinyl chloride polymer Shin-Etsu Chemical Co., Ltd. (JP) 1986-02-26 EP disclosed
US-4379929-A BACTERIOSTATS ELI LILLY AND COMPANY (US) 1983-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240207263-A1 SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE AND USES THEREOF ATM, CHEK2, CHEK1 GPR3 3578/4885IDO1 4452/4885TGFBR1 3095/4885
US-20260008767-A1 SOMATOSTATIN MODULATORS AND USES THEREOF SSTR5, SSTR3, SSTR2 GPR3 85/4885IDO1 2316/4885TGFBR1 1872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.